A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Learn more about a new study claiming that GLP-1s could be used to treat cognitive conditions like dementia, but may pose a ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.